The Effect of Adjuvant Chemotherapy on Stage Ⅳ(T4N1-3M0 and T1-3N3M0) Gastric Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose ; The optimal chemotherapeutic strategy for gastric cancer patients has not been determined, especially with respect to stage and the curability of gastric cancer. The aim of this study was to evaluate the results of adjuvant chemotherapy on stage Ⅳ(T4N1-3M0 and T1-3N3M0) gastric cancer after curative gastrectomy between a chemotherapy (CTX) group and non-chemotherapy (non-CTX) group. Materials and Methods ; Among 1,760 patients who underwent gastric surgery by 1 surgeon in a single institution, 162 stage Ⅳgastric cancer patients with curative gastrectomy were analyzed retrospectively, excluding patients with TanyNanyM1. One hundred twenty-five patients who received different chemotherapeutic regimens were compared to 37 patients who did not receive chemotherapy for reasons of old age or according to their expressed desire. Results ; The clinicopathologic factors which showed a clinically significant difference between the two groups were age and histology, which were not associated with patient survival. The CTX group was younger, and had a larger proportion of undifferentiated gastric cancers than the non-CTX group. The mode of treatment failure revealed no significant difference between the CTX and non-CTX groups. The 1, 3, and 5-year disease-free survival and the 1, 3, and 5-year disease-specific survival of the CTX group were 63.9%, 38.4%, and 32.0%, and 85.4%, 52.3%, and 39.6%, respectively, which were more favorable than the non-CTX group (p=0.015 and p=0.001, respectively). Postoperative adjuvant CTX was an independent risk factor for disease-specific survival of stage Ⅳ(T4N1-3M0 and T1-3N3M0) gastric cancer patients after curative gastrectomy by multivariate analysis (odds ratio=2.153; 95% confidence interval=1.349-3.435; p=0.001). Conclusions ; Adjuvant CTX may be associated with survival benefit for younger patients with stage Ⅳ (T4N1-3M0 and T1-3N3M0) gastric cancer with undifferentiated histology after curative gastrectomy. A randomized controlled trial to reveal the effect of stage-specific adjuvant chemotherapy should be conducted.
Abstract
Purpose ; The optimal chemotherapeutic strategy for gastric cancer patients has not been determined, especially with respect to stage and the curability of gastric cancer. The aim of this study was to evaluate the results of adjuvant chemotherapy on stage Ⅳ(T4N1-3M0 and T1-3N3M0) gastric cancer after curative gastrectomy between a chemotherapy (CTX) group and non-chemotherapy (non-CTX) group. Materials and Methods ; Among 1,760 patients who underwent gastric surgery by 1 surgeon in a single institution, 162 stage Ⅳgastric cancer patients with curative gastrectomy were analyzed retrospectively, excluding patients with TanyNanyM1. One hundred twenty-five patients who received different chemotherapeutic regimens were compared to 37 patients who did not receive chemotherapy for reasons of old age or according to their expressed desire. Results ; The clinicopathologic factors which showed a clinically significant difference between the two groups were age and histology, which were not associated with patient survival. The CTX group was younger, and had a larger proportion of undifferentiated gastric cancers than the non-CTX group. The mode of treatment failure revealed no significant difference between the CTX and non-CTX groups. The 1, 3, and 5-year disease-free survival and the 1, 3, and 5-year disease-specific survival of the CTX group were 63.9%, 38.4%, and 32.0%, and 85.4%, 52.3%, and 39.6%, respectively, which were more favorable than the non-CTX group (p=0.015 and p=0.001, respectively). Postoperative adjuvant CTX was an independent risk factor for disease-specific survival of stage Ⅳ(T4N1-3M0 and T1-3N3M0) gastric cancer patients after curative gastrectomy by multivariate analysis (odds ratio=2.153; 95% confidence interval=1.349-3.435; p=0.001). Conclusions ; Adjuvant CTX may be associated with survival benefit for younger patients with stage Ⅳ (T4N1-3M0 and T1-3N3M0) gastric cancer with undifferentiated histology after curative gastrectomy. A randomized controlled trial to reveal the effect of stage-specific adjuvant chemotherapy should be conducted.
참고문헌 (22)
- Parkin DM, "Global cancer statistics", CA Cancer J Clin, 49, pp.33~64 (1999)
- Hermans J, "Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials", J Clin Oncol, 11, pp.1441~1447 (1993)
- Panzini I, "Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses", Tumori, 88, pp.21~27 (2002)
- Liu TS, "An updated meta-analysis of adjuvant chemotherapy after curative resection for gastric cancer", Eur J Surg Oncol, 34, pp.1208~1216 (2008)
- Mari E, "Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente)", Ann Oncol, 11, pp.837~843 (2000)
- Zhao SL, "The role of postoperative adjuvant chemotherapy following curative resection for gastric cancer: a meta-analysis", Cancer Invest, 26, pp.317~325 (2008)
- Greene FL, "TNM staging for malignancies of the digestive tract: 2003 changes and beyond", Semin Surg Oncol, 21, pp.23~29 (2003)
- Oken MM, "Toxicity and response criteria of the Eastern Cooperative Oncology Group", Am J Clin Oncol, 5, pp.649~655 (1982)
- Aurello P, "Classification of lymph node metastases from gastric cancer: comparison between N-site and Nnumber systems. Our experience and review of the literature", Am Surg, 73, pp.359~366 (2007)
- Noguchi M, "Prognostic significance and surgical management of lymph node metastasis in gastric cancer", Br J Surg, 83, pp.156~161 (1996)
- Di Costanzo F, "Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC", J Natl Cancer Inst, 100, pp.388~398 (2008)
- Sakuramoto S, "Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine", N Engl J Med, (357), pp.1810~1820 (2007)
- Nashimoto A, "Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1", J Clin Oncol, 21, pp.2282~2287 (2003)
- Bajetta E, "Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group", Ann Oncol, 13, pp.299~307 (2002)
- Neri B, "Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up", Br J Cancer, 84, pp.878~880 (2001)
- Cunningham D, "Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer", N Engl J Med, 355, pp.11~20 (2006)
- Macdonald JS, "Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction", N Engl J Med, 345, pp.725~730 (2001)
- Sobrero A, "Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? For the proposal", Lancet Oncol, 7, pp.515~516 (2006)
- Quah HM, "Identification of patients with high-risk stage II colon cancer for adjuvant therapy", Dis Colon Rectum, 51, pp.503~507 (2008)
- Nakajima T, "Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosanegative, locally advanced gastric cancer", Br J Surg, 94, pp.1468~1476 (2007)
- Benson AB 3rd, "American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer", J Clin Oncol, 22, pp.3408~3419 (2004)
- Verdecchia A, "Explaining gastric cancer survival differences among European countries", Int J Cancer, 109, pp.737~741 (2004)